A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
The conversation discusses the potential use of thermal paper receipts, which contain estrogen, as a treatment for hair loss. Participants humorously debate its effectiveness compared to established treatments like Minoxidil and finasteride.
Hair loss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.
The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
Two twins who used Minoxidil, finasteride and dermarollers to treat their androgenic alopecia over a 10 month time period. The user is providing details on the process they use for dermarolling.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Vitamin D deficiency is linked to hair loss, and supplementation with vitamin D can improve conditions like androgenic alopecia and telogen effluvium. Users discussed various dosages of vitamin D, emphasizing the importance of getting blood tests to determine the appropriate amount.
Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.
A user shared a 9-month hair recovery journey from androgenic alopecia using 1 mg finasteride daily, 5% minoxidil twice daily, and weekly dermarolling with a 1.5 mm roller. Some responders were skeptical about the authenticity of the results, while others confirmed the consistency of the user's appearance and supported the effectiveness of the treatment.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Topical formulations, natural products, and CAM therapies are being used to treat Androgenic alopecia to avoid side effects of Finasteride and Minoxidil. The review covers various low-risk, alternative treatment options.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.
The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.
The dermatologist diagnosed androgenic alopecia and prescribed minoxidil and a shampoo for dandruff, avoiding finasteride due to side effects. The user questions the dermatologist's approach and considers seeking a second opinion due to concerns about the lack of a physical scalp check initially.
A woman with androgenic alopecia has been using birth control, spironolactone, finasteride, and oral minoxidil for hair loss. She sought to change her medications to dutasteride and bicalutamide, but her new dermatologist refused to prescribe them for off-label use.
A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.
Treatments for androgenic hair loss, including the use of finasteride, minoxidil, nizroal and microneedling/dermarolling. Side effects are discussed and it is noted that while there are tradeoffs to taking medications, they are generally safe and effective.
27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.
A user discusses their hair loss and current natural treatments, including derma stamp, rosemary oil, wild growth hair oil, biotin, omega 3, and a small DHT blocker. Another user suggests the hair loss is androgenic alopecia and recommends either taking finasteride or accepting the hair loss.
A user is asking women with androgenic alopecia about the effective dose of spironolactone for hair regrowth, mentioning they've been on 100 mg for a year with minimal results and considering increasing the dose. The conversation focuses on the effectiveness of spironolactone for hair loss treatment.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.